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Abstract
Background: The World Health Organization has urged all member states to deploy artemisinin-based combination
therapy and progressively withdraw oral artemisinin monotherapies from the market due to their high recrudescence
rates and to reduce the risk of drug resistance. Prescription practices by physicians and the availability of oral
artemisinin monotherapies with pharmacists directly affect the pattern of their use. Thus, treatment practices for malaria,
with special reference to artemisinin monotherapy prescription, in selected states of India were evaluated.
Methods: Structured, tested questionnaires were used to conduct convenience surveys of physicians and
pharmacists in eleven purposively selected districts across six states in 2008. In addition, exit interviews of patients
with a diagnosis of uncomplicated malaria or a prescription for an anti-malarial drug were also performed. Logistic
regression was used to determine patient clinical care, and institutional factors associated with artemisinin
monotherapy prescription.
Results: Five hundred and eleven physicians from 196 health facilities, 530 pharmacists, and 1, 832 patients were
interviewed. Artemisinin monotherapy was available in 72.6% of pharmacies and was prescribed by physicians for
uncomplicated malaria in all study states. Exit interviews among patients confirmed the high rate of use of
artemisinin monotherapy with 14.8% receiving such a prescription. Case management, i.e. method of diagnosis and
overall treatment, varied by state and public or private sector. Treatment in the private sector (OR 8.0, 95%CI: 3.8,
17) was the strongest predictor of artemisinin monotherapy prescription when accounting for other factors. Use of
the combination therapy recommended by the national drug policy, artesunate + sulphadoxine-pyrimethamine,
was minimal (4.9%), with the exception of one state.
Conclusions: Artemisinin monotherapy use was widespread across India in 2008. The accessible sale of oral artemisinin
monotherapy in retail market and an inadequate supply of recommended drugs in the public sector health facilities
promoted its prescription. This study resulted in notifications to all state drug controllers in India to withdraw the oral
artemisinin formulations from the market. In 2010, artesunate + sulphadoxine-pyrimethamine became the universal
first-line treatment for confirmed Plasmodium falciparum malaria and was deployed at full scale.
Background
Artemisinin-based combination therapy (ACT) has been
the mainstay treatment for Plasmodium falciparum
malaria in Southeast Asia for more than 10 years and is
now recommended as the first-line treatment throughout
the world [1]. Artemisinins produce rapid therapeutic
response, reduce gametocyte carriage, and are well toler-
ated by patients [2]. The World Health Organization
(WHO) also recommends the use of artemisinin derivatives
only in combination with effective partner drugs to ensure
high cure rates and delay resistance. The five formulations
of ACT recommended by WHO are artemether + lume-
fantrine, artesunate + mefloquine, artesunate + amodia-
quine, artesunate + sulphadoxine-pyrimethamine and
dihydroartemisinin + piperaquine [3].* Correspondence: neenavalecha@gmail.com1National Institute of Malaria Research (NIMR), Indian Council of Medical
Research, Sector 8, Dwarka, New Delhi 110 077, India
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In India, the national treatment policy prior to 2008
recommended chloroquine for P. falciparum and P. vivax
treatment in areas where therapeutic studies had not been
conducted or where treatment failure was less than 10%.
However, systematic analyses of chloroquine resistance
suggested the phenomenon was widespread [2,4], not focal,
and ACT was introduced by the National Vector Borne
Disease Control Programme (NVBDCP) as the first-line
treatment of falciparum malaria in 117 districts which
represented more than 90% of the reported P. falciparum
cases [5]. Presently all formulations of ACT recommended
by WHO, except dihydroartemisinin + piperaquine, are
registered with the Drug Controller General of India. In
the public sector health system only artesunate + sulpha-
doxine-pyrimethamine blister packs were recommended
though the combination was supplied as loose tablets as
well.
The success of a new treatment policy depends on the
adherence of health providers to the guideline and the
compliance of patients with the recommended treatment.
Equally, information on current provider and patient prac-
tices is needed to inform and improve future treatment
policy. Recent reports note changes in pattern of drug pre-
scription and utilization in public and private health facil-
ities following changes in national treatment policy [6,7].
However, inappropriate treatment practices continue in
spite of the availability of evidenced-based guidelines [8].
Informal assessments and earlier studies in the Indian
public and private sector suggest a substantial burden of
incorrect treatments and an irrational use of antibiotics
and injectables [9]. Large-scale evaluations of the state of
anti-malarial treatment patterns, including the prescrip-
tion of artemisinin monotherapy, were not available in
India. Therefore, the treatment practices of physicians,
patient experiences, and anti-malarial drug availability in




Six states were selected: Assam, Delhi, Goa, Gujarat, Jhark-
hand, and Orissa. Out of these, Assam, Jharkhand, and
Orissa were priority states for P. falciparum control repre-
senting 55.1% of the reported burden in the country [5].
The other three states represented different transmission
settings to provide a more representative national picture.
In Goa, most malaria is associated with high-risk labour
migration, while Gujarat is a low transmission setting with
both major malaria species, and in Delhi local transmis-
sion is of P. vivax only. In each state, except Delhi, two
districts (third level administrative unit of one to three
million population) were selected based on the proportion
of P. falciparum among all malaria (≥50%) in the district
from surveillance data and the introduction of ACT by
NVBDCP.
Study design
A cross-section of conveniently selected health facilities in
each site were surveyed during August to November 2008.
Different levels of health facilities including district hospi-
tals, primary health centres (PHC), subcentres, and private
hospitals or clinics were interviewed. All physicians pre-
sent in the selected health facility were interviewed. Sur-
veys were also conducted amongst all pharmacists around
a 5 km radius of selected health facilities. Finally, exit
interviews were conducted in all patients leaving the
selected health facility that day with either a diagnosis
(clinical or laboratory) of malaria or to whom anti-malarial
medicines were prescribed. An earlier study in Jharkhand
described 17% artemisinin monotherapy (Mishra et al.,
unpublished data) among treatments. With 90% power
and an alpha of 0.05, at least 1, 733 patients would be
needed to detect a 20% prevalence in such a setting.
Data collection
Each interview team included one experienced surveyor
and a trained supporting staff. Data was collected using
pre-structured and pre-tested questionnaires. Physicians
were interviewed about their years of experience in pro-
viding health services, educational qualifications, use of
blood slide or rapid diagnostic kit (RDK) for diagnosis,
and the prescription and frequency of use of different
anti-malarials. Patients were interviewed about their
symptoms, the diagnostic workup received along with its
result, and drugs prescribed (if any). In the case of minor
children, guardians/parents were interviewed. Paper
records of the visit, tests, and prescription were also
examined, if available. Pharmacists were interviewed and
asked about the availability and sale of all anti-malarials
in their stock.
Data analysis
A single data entry staff recorded results using Micro-
soft Excel 2003 and each entry was cross-checked by a
senior investigator. Range checks were used to detect
implausible values. Data analysis was conducted with
STATA v10. Questionnaire responses were summated,
physician characteristics were compared by public and
private sector status, and diagnostic and treatment indi-
cators were compared by state. Logistic regression was
used to determine adjusted odds ratios for facility and
clinical factors associated with artemisinin monotherapy.
All univariate variables were included in the multivari-
able model except in the case of collinear predictors
where the model with the better fit (lower AIC criter-
ion) was retained.
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Ethics
Verbal consent was obtained from all interviewees, data
was de-identified, and the Scientific Advisory Committee
of the National Institute of Malaria Research approved
the study design and questionnaires. The study was a
public health program evaluation conducted at the
request of NVBDCP and thus IRB exempt.
Results
Five hundred and eleven physicians and 1, 832 patients
were interviewed in 98 private and 98 public sector
health facilities (Table 1) along with 530 pharmacists.
No physician, patient, or pharmacists declined an inter-
view. Public sector physicians had fewer years of clinical
experience on average but a higher proportion of them
had post-graduate training in medicine compared to
physicians in the private sector. A high proportion of
private sector physicians were non-allopathic trained.
Case management practices by physicians for
uncomplicated malaria
Most physicians (62.2%) reported using both slides and
RDKs for diagnosis. A higher proportion of private sector
physicians used RDKs exclusively (9.2%) compared
to those in the public sector (1.6%). Private sector physi-
cians ‘always’ prescribed more artemisinins alone,
artemisinin plus other anti-malarials, and less artesunate
+ sulphadoxine-pyrimethamine (18.5%, 7.8%, 10.2% of
prescriptions respectively) versus those in the public sec-
tor (6.9%, 3.6%, 14.1%) (Table 2). Chloroquine was the
most frequently prescribed anti-malarial drug in both
sectors. Statewise ‘always’ prescription of artesunate
alone and of artesunate + sulphadoxine-pyrimethamine
was highest in Jharkhand and Orissa, and Goa and Orissa
respectively (Table 2).
Anti-malarial treatments prescribed to patients
Exit interviews results show a wide range of anti-malarial
groups and treatments, as well as primaquine and antibio-
tics, were prescribed to 93.8% of patients (Table 3). There
were fifteen different treatment regimens recorded and the
majority of patients received non-artemisinin monother-
apy for the treatment of suspected or confirmed malaria.
Artemisinin monotherapy represented 14.8% of the total
prescriptions while recommended ACT represented 4.9%
and other artemisinin combinations were 5.6% of the total.
Overall, the co-prescription of primaquine was 34% reach-
ing 87% among confirmed P. vivax patients in the public
sector and 52% in private health facilities. The co-adminis-
tration of antibiotics, 13.6% overall, was highest with
chloroquine (n = 74) followed by patients without anti-
malarial prescription (n = 23).
Table 1 Characteristics of 511 interviewed physicians by sector, India, 2008
Public Private Total
Characteristic n % n % n %
State
Assam 75 24.6 33 16.0 108 21.1
Goa 46 15.1 20 9.7 66 12.9
Gujarat 47 15.4 45 21.8 92 18.0
Delhi 44 14.4 28 13.6 72 14.1
Jharkhand 55 18.0 50 24.3 105 20.6
Orissa 38 12.5 30 14.6 68 13.3
Facility type
District hospital/nursing home 176 58.1 124 60.5 300 58.8
PHC, subcentre/clinic 101 33.3 46 22.4 147 28.8
Other 28 9.2 35 17.1 63 12.4
Experience (years)
< 2 39 12.9 11 5.4 50 9.8
2-10 94 31.0 56 27.3 150 29.5
10-20 94 31.0 66 32.2 160 31.5
> 20 76 25.1 72 35.1 148 29.1
Education
MBBS 131 43.0 74 35.9 205 40.1
Post-graduate 149 48.9 81 39.3 230 45.0
Non-allopathic 25 8.2 51 24.8 76 14.9
Missing: facility type (1), experience (3)
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Patient experiences of physician case management
1, 600 patients in public and 232 patients in private health
facilities were interviewed. Of these, 91% received some
blood test with microscopy as the main diagnostic test
(73.5%), followed by RDK (18.5%), and 7.3% were tested
with both RDK and microscopy together (Figure 1). The
use of artesunate monotherapy was 29.8% among con-
firmed P. falciparum patients, 5.5% for P. vivax, 2.7% for
those with unknown diagnosis, 6.6% in those with negative
reports, and 25.7% in patients with clinical assessment
alone (Figure 1). Rational treatment, i.e. a non-anti-malarial
prescription, was higher in smear negative patients (16.2%)
compared to those who were tested using RDK or both
(9.8%). The proportion of clinically diagnosed patients,
those receiving artemisinin monotherapy, confirmed P. fal-
ciparum among total confirmed as well as the proportion
of the former diagnosed by RDK were all highest in Jhark-
hand (Figure 2). Notably, 78% of confirmed P. falciparum
patients in Goa received ACT (artesunate + sulphadoxine-
pyrimethamine). Patients who were prescribed artemisinin
monotherapy versus other regimens were compared by
facility, patient, and management risks (Table 4). The pre-
scription of artemisinin monotherapy was higher in hospi-
tals, patients 15 years or older, government health facilities,
Table 2 Prescribing frequency (%) of different anti-malarials by 511 interviewed physicians by sector or state, India,
2008
Public Private
Treatment Always Often Some Rarely Never Always Often Some Rarely Never
Chloroquine 63.6 18.0 6.6 4.3 7.2 57.3 7.3 14.1 3.9 17.5
SP 1.6 5.6 13.4 10.8 68.2 2.9 10.7 6.8 11.2 68.5
Mefloquine 1.0 1.6 7.2 9.2 80.7 1.5 1.5 6.8 5.8 84.5
Quinine 7.2 22.6 23.3 11.8 34.8 10.7 16.5 15.5 17.5 39.8
ASP 14.1 11.2 20.0 8.5 45.9 10.2 12.1 10.2 5.8 61.7
As alone 6.9 20.0 23.3 12.5 37.1 18.5 20.9 16.0 12.1 32.5
As+other 3.6 4.9 10.8 7.2 73.1 7.8 3.9 4.9 4.9 78.6
Assam Goa
Chloroquine 65.7 14.8 9.3 2.8 7.4 87.9 6.1 1.5 0.0 3.0
SP 0.9 6.5 15.7 18.5 58.3 3.0 1.5 4.6 9.1 80.3
Mefloquine 0.0 0.0 3.7 7.4 88.9 4.6 3.0 6.1 12.1 72.7
Quinine 10.2 29.6 29.6 17.6 13.0 6.1 1.5 16.7 22.7 51.5
ASP 4.6 12.0 21.3 8.3 53.7 47.0 12.1 12.1 9.1 18.2
As alone 6.5 18.5 27.8 11.1 36.1 9.1 4.6 4.6 3.0 77.3
As+other 4.6 0.9 1.9 0.9 90.7 13.6 0.0 1.5 3.0 78.8
Gujarat Delhi
Chloroquine 79.4 2.2 1.1 1.1 16.3 55.6 34.7 1.4 0.0 8.3
SP 1.1 5.4 6.5 1.1 85.9 2.8 15.3 18.1 12.5 51.4
Mefloquine 0.0 1.1 1.1 1.1 96.7 2.8 2.8 23.6 8.3 62.5
Quinine 5.4 10.9 10.9 8.7 64.1 2.8 16.7 18.1 9.7 52.8
ASP 1.1 2.2 5.4 1.1 90.2 1.4 5.6 20.8 11.1 61.1
As alone 13.0 15.2 22.8 15.2 33.7 8.3 19.4 11.1 18.1 43.1
As+other 14.1 2.2 1.1 1.1 81.5 1.4 4.2 1.4 2.8 90.3
Jharkhand Orissa
Chloroquine 47.6 10.5 15.2 9.5 17.1 29.4 17.7 29.4 10.3 13.2
SP 3.8 12.4 8.6 11.4 63.8 1.5 2.9 10.3 11.8 73.5
Mefloquine 1.0 1.0 8.6 12.4 77.1 0.0 2.9 1.5 5.9 89.7
Quinine 13.3 31.4 16.2 9.5 29.5 11.8 22.1 29.4 19.1 17.7
ASP 6.7 14.3 14.3 10.5 54.3 27.9 25.0 23.5 4.4 19.1
As alone 15.2 30.5 28.6 15.2 10.5 17.7 30.9 17.7 8.8 25.0
As+other 1.9 1.0 1.9 3.8 91.4 7.4 0.0 0.0 0.0 92.7
305 public (1 missing) and 206 private physicians, As - artemisinin, As alone - artemisinin monotherapy, SP - sulphadoxine-pyrimethamine, ASP - artesunate+SP
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cases screened by RDK, and in P. falciparum confirmed
patients. Adjusting for multiple risks, patients in Delhi and
Jharkhand, exiting private health facilities, 15 years or older,
and with mixed or confirmed P. falciparum infections had
higher odds for receiving an artemisinin monotherapy pre-
scription (Table 4).
Anti-malarial availability and sale in the pharmacy shop
Among 530 pharmacy shops, 72.6% reported the sale of
artemisinin derivatives alone in the past year. Of these,
44.2% of sales were injectable derivatives. The most
common drug sold across the counter was chloroquine.
Goa and Delhi had the high unavailability of artemisinin
(46.3%, 55.6%) while the highest proportion of shops
having sold injectable artemisinin derivatives were in
Assam and Jharkhand (71.3%, 66.1%).
Discussion
Artemisisin monotherapy was widely available in Indian
pharmacies and frequently prescribed by according to
both patient and physician interviews. Overall case man-
agement varied between the public and private sector as
well as region.
Artemisinin monotherapy
The inappropriate use of anti-malarials in the past has
contributed to decreased drug sensitivities today [10].
Recent therapeutic efficacy studies along the Thai-Cam-
bodia border described an increased proportion of
patients who were parasitaemic on the third day of fol-
low-up, indicating reduced parasite susceptibility to arte-
misinins in an area where oral artemisinin
monotherapies were widely available [11]. In this study,
the easy accessibility, unregulated sale of oral artemisinin
monotherapy in the retail market, and inadequate avail-
ability of the recommended ACT in public and private
health facilities were key contributors. In informal dis-
cussions with physicians, other factors hindering the
implementation of the new policy were the inertia of
practitioners in accepting new treatments, lack of aware-
ness about the new drug policy, and fear of stock outs.
The widespread availability of artemisinin monotherapy
in both oral and injectable forms, and the different poli-
cies surrounding each, also caused prescription confu-
sion. Notably, monotherapy use was strongly associated
with private sector care in multivariable analysis where a
higher proportion of physicians were non-allopathic.
Unsurprisingly, monotherapy use was higher in both
P. falciparum patients and P. falciparum areas. After that
however, use was highest among patients who did not
receive a blood test and were treated clinically. Dodoo
et al. reported similar results from Ghana where the pre-
scription of artesunate monotherapy was highest in blood
smear positive patients (32.9%) followed by patients with-
out blood tests (21%), underscoring the need for dis-
couraging presumptive treatment [12].
Rational case management
Proper case management, guided by a laboratory diagno-
sis, reduces the overconsumption of all anti-malarials,
including artemisinin monotherapy. Presumptive treat-
ment in India is discouraged and over 90% of patients in
both sectors received a blood test and only a small propor-
tion of patients testing negative or unknown received arte-
misinin monotherapy. However, many smear or RDK
negative patients still received another anti-malarial sug-
gesting a lack of confidence in the diagnosis and/or a lack
of concern about the overuse of anti-malarials. In the case
of patients tested with RDK alone and microscopy is not
available, treatment for vivax malaria may be reasonable as
all kits in the public sector were monovalent and detect
P. falciparum alone. Radical treatment, anti-relapse ther-
apy for P. vivax or anti-gametocidal therapy for P. falci-
parum, using primaquine is also an important goal for
control. At the time of the study no guidelines for the use
of primaquine with ACT in uncomplicated P. falciparum
malaria were available. For confirmed vivax malaria most
patients seen in the public sector received a prescription
Table 3 Anti-malarial groups and treatments prescribed
to patients as well as primaquine and antibiotics from
exit interviews, India, 2008
Drug group/treatment n % PQ Abx
Artemisinin monotherapy 271 14.8 6 75
Non-artemisinin monotherapy 1, 241 68.0 520 98




WHO ACT 89 4.9 37 2
ASP blister 30 2




Non-WHO ACT 102 5.6 8 35
As+CQ 63 7 19
As+Q 37 15
As+CQ+Q 2 1 1
Non-artemisinin combination 15 0.8 7 0
CQ+SP 13 7
CQ+Q 2
No anti-malarial drug 108 5.9 0 23
Missing 6
1832 583 233
CQ - chloroquine, SP - sulphadoxine-pyrimethamine, Q - quinine, As -
artemisinin derivative, ASP - artesunate+SP, PQ - primaquine, Abx - antibiotic
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for primaquine but only half of those in the private sector
did. Whether the dose and duration of treatment, as well
as counselling for side-effects, were appropriate is
unknown. Finally, the co-administration of antibiotics in
uncomplicated malaria cases was frequent and is a cause
for concern.
Scaling Up ACT
This study was conducted in 2008 about 1 year after
ACT became the recommended treatment of P. falci-
parum cases in limited areas: demonstrated chloroquine
resistance, malaria deaths, high proportion of P. falci-
parum. A total of 117 districts were eligible and repre-
sented the majority of the reported falciparum malaria
burden of the country. ACT blister packs were deployed
through NVBDCP for 15 years or older age groups and
efforts to produce blister packs for other age groups
were ongoing. In this study all of the sampled districts
were targeted for ACT except for Delhi. However, the
use of ACT for confirmed P. falciparum cases was low
with the exception of Goa. International attention has
focused on identifying sustainable resources for purchas-
ing the needed drugs for widespread deployment
through public sector health systems [13]. In India, this
is less of a concern where substantial funding was avail-
able through the central government. The effective
implementation of ACT needs active participation at all
levels including members from the periphery health ser-
vices due to the complex federal structure of the nation
and its large size and population. Supply chain improve-
ment and training to dispense the correct dose of ACT
is required, particularly to paramedical health workers
whose literacy is nominal. The current product profile
of ACT used in the country also requires improvement
to simplify prescription and promote higher adherence
to treatment. They were available exclusively as co-blis-
tered products for adults (> 15 years of age; artesunate
in combination with sulphadoxine-pyrimethamine). Lack
of availability of different age-specific courses of therapy
and short shelf-life (2 years) were other limitations.
Figure 1 Flow chart of patient case management from exit interviews, India, 2008. NA - non-artsesunate treatment, AM - artesunate
monotherapy, ACT - WHO or non-WHO ACT, NM - non-antimalarial.
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Limitations
This study was conducted in 2008 relatively soon after
the first widespread introduction of ACT in country.
Even blister packs for different age groups were unavail-
able necessitating supply of loose tablets of artesunate
to be made available in the PHC which may have
increased monotherapy use. As the study was conducted
for public health needs, important areas were purpo-
sively selected rather than random sites and the results
may not be population representative. Physician and
pharmacist responses may have been biased to appear
desirable, however, confidentiality was stressed and par-
ticipation was 100%.
Conclusions
Following this study, strict regulation on industry as well
as retail outlets was imposed by the Drug Controller
General of India leading to a total ban on the sale of
Figure 2 State wise treatment (top) and diagnosis (bottom) trends from patient interviews, India, 2008. Treatment legend (top): AM -
artesunate monotherapy, PF w/ACT - Diagnosed P. falciparum cases prescribed WHO ACT, PV w/PQ - Diagnosed P. vivax cases prescribed
primaquine. Diagnosis legend (bottom): Not tested - patients who did not receive a blood test, PF% - proportion of P. falciparum and mixed
infection among diagnosed cases, PF w/RDK - P. falciparum cases diagnosed by RDK.
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oral artemisinin monotherapy since July 2009. Creating
awareness among health providers to change clinical
practices remains the greatest challenge, particularly in
the large private sector. Fixed dose combinations, which
prevent the accidental or intentional use of artemisinin
monotherapy, are the best available option for future
policy. Ensuring access to effective ACT in both public
and private sectors, while progressively removing oral
artemisinin monotherapies from the market, is essential
to provide effective treatment and prevent the develop-
ment of artemisinin resistance.
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None 35 129 21.3 2.9 1.9, 4.4
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Malaria positive 194 621 23.8 –
Malaria negative 36 503 6.7 0.2 0.2, 0.3
Unknown 8 298 2.6 0.1 0.0, 0.2
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P. vivax 18 306 5.6 – –
P. falciparum 166 305 35.2 9.3 5.4, 16 4.2 2.2, 7.8
Mixed infection 4 6 40.0 11 2.8, 46 5.0 0.9, 28
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